Elucidation of the biological characteristics of lymph node stromal cells and the application to drug therapy

Research Project

Project/Area Number	18K08323
Research Category	Grant-in-Aid for Scientific Research (C)
Allocation Type	Multi-year Fund
Section	一般
Review Section	Basic Section 54010:Hematology and medical oncology-related
Research Institution	Fujita Health University
Principal Investigator	MIURA YASUO 藤田医科大学, 医学部, 教授 (70605146)
Project Period (FY)	2018-04-01 – 2023-03-31
Project Status	Completed (Fiscal Year 2022)
Budget Amount *help	¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000) Fiscal Year 2020: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000) Fiscal Year 2019: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000) Fiscal Year 2018: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Keywords	造血器腫瘍 / 間葉系間質細胞 / 間質細胞 / リンパ腫 / 腫瘍微小環境 / 間葉系幹細胞 / 抗がん剤抵抗性
Outline of Final Research Achievements	Various immune cells exist in the lymph node tissue, which is the main site of lymphoma lesions. In this study, we demonstrated the presence of mesenchymal stromal cells, which are recognized as one of the regulatory immune cells, in lymph node tissue. They have distinct biological characteristics from bone marrow-derived mesenchymal stromal cells, using a combination of cell culture and immunohistochemical and gene expression analyses. Furthermore, we showed that pharmacological stimulation can suppress the growth-supportive ability of lymphoma cells by mesenchymal stromal cells.
Academic Significance and Societal Importance of the Research Achievements	悪性腫瘍であるリンパ腫において腫瘍微小環境を標的とした薬物治療が有効であることの概念実証を示したことに学術的意義がある．わが国のガン統計によると，リンパ腫死亡者数は年間1万人以上で増加の一途をたどっており，薬物療法の基盤開発を通したがん対策の観点から社会的意義がある．